Histogen Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Currently, we are developing emricasan for ABSSSI as well evaluating its use for other infectious diseases. Our pipeline also includes novel preclinical product candidates including CTS-2090 and other proprietary caspase inhibitors, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases.
No news available
Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.
